Abstract
We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| Journal | Genes and Diseases |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1 2017 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ANG1005
- Brain metastasis
- Breast cancer
- LRP-1
- The blood-brain-barrier
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Genetics(clinical)
- Cell Biology
Fingerprint
Dive into the research topics of 'Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS